Anzeige
Mehr »
Login
Sonntag, 03.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H48J | ISIN: SE0009973563 | Ticker-Symbol: 6XP
Stuttgart
01.11.24
14:46 Uhr
5,080 Euro
+0,010
+0,20 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XSPRAY PHARMA AB Chart 1 Jahr
5-Tage-Chart
XSPRAY PHARMA AB 5-Tage-Chart

Aktuelle News zur XSPRAY PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.09.Xspray Pharma AB: Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission198Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology to develop enhanced cancer therapies, today announced significant progress...
► Artikel lesen
06.09.Scientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology329A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap technology improves the bioavailability and reduces variability of...
► Artikel lesen
07.08.XSpray Pharma AB: Interim Report Second Quarter 202489April-June 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -53,620 thousand (-51,402)Earnings per share before dilution amounted to SEK -1.64 (-2.27)Cash flow from...
► Artikel lesen
26.07.XSpray Pharma AB: Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development307Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Dasynoc...
► Artikel lesen
09.07.Xspray Pharma AB: Xspray Pharma's XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose304Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. Xspray Pharma AB (Stockholm/Nasdaq:...
► Artikel lesen
08.05.XSpray Pharma AB: Interim Report First Quarter 2024152January-March 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -67,781 thousand (-34,827)Earnings per share before dilution amounted to SEK -2.17 (-1.54)Cash flow from...
► Artikel lesen
14.02.XSpray Pharma AB: Interim Report Fourth Quarter 2023300October-December 2023, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -54,513 thousand (-55,220)Earnings per share before dilution amounted to SEK -1.85 (-2.48)Cash flow...
► Artikel lesen
12.02.FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc - PDUFA Date set to 31 July 2024300Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma's New Drug Application (NDA) for Dasynoc, following...
► Artikel lesen
21.11.23Xspray Pharma AB: Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage426XS003, an amorphous non-crystalline nilotinib, designed to overcome therapeutic limitations of the currently available crystalline formulation of nilotinib (TASIGNA®), is the second protein kinase...
► Artikel lesen
08.11.23Xspray Pharma AB: DASYNOC Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL Uptake is Significantly More Impaired than Previously Understood443DASYNOC (Xspray's low dose, amorphous, non-crystalline, dasatinib) avoids interactions with proton pump inhibitors (PPIs), making it potentially the first and only dasatinib to provide patients...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1